{
    "headline": "HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV",
    "publish_date": "02/15/22 3:05 PM",
    "content": "NEW YORK and VIENNA, Austria, Feb. 15, 2022\n(GLOBE NEWSWIRE) -- HOOKIPA Pharma\n\nInc. (NASDAQ: HOOK, HOOKIPA), a company\ndeveloping a new class of immunotherapeutics\nbased on its proprietary arenavirus platform,\ntoday announced it has entered into an amended\nand restated collaboration and license agreement\nwith Gilead to advance the development of a\nnovel arenaviral immunotherapy as a component\nof a potential functional curative regimen for\nhuman immunodeficiency virus (HIV).\n\nIn April 2018, Gilead licensed exclusive rights\nto HOOKIPA\u2019s versatile arenaviral platform to\ndevelon immunotheranies for HIV and henatitis B",
    "ticker": "HOOK",
    "ticker_code": "(NASDAQ: HOOK, HOOKIPA)"
}